The (Virtual) Show Must Go On!

2 Apr

By Karen Deyo, Senior Investor Research Analyst, LSN

Did Digital RESI live up to expectations? You bet!

One investor, David Gordon, Head of Investments at Longliv Ventures, wrote the following article on LinkedIn. In it, he says “In less than two days, from the comfort of my home office, I saw some very exciting deal flow pitches and got to know more than a dozen potential investment partners. See in the picture Steve Seuntjens of PHS (Personal Health Solutions) and myself, enjoying a quick and good meeting of the minds.”

In addition to David’s comments, the following investors sent us the following feedback.

Bill Kuziel, an Investor at MedPro Investors, shared that he had many meetings on the first day, and all of them went off without a hitch.
Aaron Sandoski, Co-Founder and Managing Director of Norwich Ventures, even shared, “Actually, I preferred it to in-person meetings since the flexibility of the multi-day approach made it much easier to fit conversations into my schedule.”
Haifeng Cui, Senior Director, Scientific Innovation at Johnson & Johnson Innovation said “I really enjoyed the digital RESI meetings, very easy to use and convenient. Given the experience I had, I am highly interested to participate for the next two events.”
Jim Burden, President of Dorset Capital, made a note of mentioning that they would be following up with companies they ‘met’ at Digital RESI. As Jim said, “We intend to pursue at least three companies we both found interesting and worthwhile through the event. You stepped up to the challenge of one of the first video conferences and it was a success.”

We appreciate all of the support we have received from our investor network. It is not too late to sign up to our upcoming digital events, taking place on April 29-30 and June 8-10. To see a list of attending investors, make sure to take a look at this article!

Come Join These Registered Investors at the Upcoming Digital Events

2 Apr

By Joey Wong, Investor Research Analyst, LSN

After we concluded the first ever Digital RESI Conference with overwhelmingly positive feedback, we decided to launch 2 more digital events – the 2-Day Dedicated Partnering Event (April 29-30th) and the 3-Day Digital RESI Conference (June 8-10th), in order to continue facilitating valuable connections between startups and investors during this difficult time. Since announcing these two events, we have received so much support from investors across the globe, with over 100 investors signed up just within this week. We are expecting over 200 global investors to participate in the two events.

Below is a partial list of registered investors for the Dedicated Partnering Event and the Digital RESI conference – register now to meet them digitally. Hope to “see” you at our upcoming RESI events!

Confirmed Digital RESI Investors and Strategic Partners

Hot Investor Mandate: China-Based Global Healthcare Fund Invests Up to $10M in Global Healthcare Opportunities with China Market Potential

2 Apr

A China-based healthcare fund focuses on global growth opportunities. The company is based in Shanghai with additional offices in USA and China. In 2015, the firm launched a VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through this early-stage fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, healthcare IT and services. In terms of disease areas, The firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, C-Bridge only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Firm Invests in USA & Taiwan-Based Early-Stage Medical Devices, Diagnostics, and Digital Health Companies

2 Apr

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs. The firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its latest fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firms open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from USA and Taiwan.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Actively Seeks Investment Opportunities in USA & Europe-Based Therapeutics, Devices, Diagnostics Companies

2 Apr

A venture capital firm based in Western Europe is investing from its most recent fund closed in 2016. The firm makes equity investments in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €4M to €10M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan PE Firm Seeks New Investment Opportunities with Strongest Interest in Therapeutics, Devices, Digital Therapeutics

2 Apr

A private equity firm based in headquartered in Japan has a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, but may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine.  The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area, and invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor.  For early stage opportunities, the firm prefers that the company has a clinical trial plan in place.  While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Congratulations to our Digital RESI “Europe” Innovation Challenge Winners!

26 Mar

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day digital RESI “Europe” event came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. This was a very special Innovation Challenge for the RESI team as all of the poster presentations were held in digital format, with each finalist company having a dedicated page where you could view their poster, short pitch, and other supplementary materials that the companies made available for viewing.

We will keep our RESI Europe “live agenda” page open to the public for another month, so if you have not had the chance already, please visit Digital RESI Europe Live Agenda to see our virtual exhibit of some amazing technologies across therapeutics, medical devices, diagnostics, and digital health!

We would like to thank every Innovation Challenge company for quickly adapting to our digital transition, and we hope that all companies were able to make the most out of the digitally presented Innovation Challenge.

Congratulations to the Top 3 winners, and thank you all for casting your votes!

First Place: Cerebriu A/S

Click Here to Check Out Cerebriu’s Digital Poster

Cerebriu is dedicated to improving workflow efficiency, quality and patient outcomes in diagnostic imaging.

Our software solution Cerebriu Apollo achieves this by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of the diagnostic process. We offer workflow efficiency gains that result in improved productivity, better use of resources, and prioritization of the patients who need it most.

Initial focus is brain, namely tumors, haemorrhage and infarcts. Future roadmap expands to additional pathologies, body parts and advanced integration with hospital systems.

Second Place: MOWOOT

Click Here to Check Out MOWOOT’s Digital Poster

MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.

MOWOOT offers a CE certified (Med.Dev. class IIa), IP protected, clinically validated and award-winning technology: the first Intermittent Colonic Exo-peristalsis (ICE) device on the market handling a large unmet need for patients with Neurogenic-Bowel-Disorders (NBD), Idiopathic Chronic Constipation (ICC) and Opioid-Induced-Constipation (OIC).

The Global Market for the indication “chronic constipation” alone has an annual worth of US$ 12.58 bn, with a healthy CAGR of 7.1%, estimated to reach US$ 22,93 bn by 2025.

Third Place: Injeq Oy

Click Here to Check Out Injeq’s Digital Poster

IQ-Needle is a hypodermic needle which can tell where its tip is. This makes demanding blind punctures, such as spinal tap, much easier and safer for the patient. Technology is based on measuring the impedance of the tissue the tip is touching using proprietary stylet design, allowing the needle bosy and styulet to be used as electronic measurement probes. IQ-Needle and Analyzer are in pre-production as we are finalizing clinical trials and starting the CE certification process with TÜV SÜD in Germany.

← Older Entries
Newer Entries →